IL6 and rheumatoid arthritis: Treatment with the anti-TNF agent infliximab and the anti-IL-6 agent tocilizumab dramatically reversed the global downregulation of miRNAs in RA neutrophils, improved miRNA processing and decreased the production of various cytokines and chemokines, which blocked the activation of RA neutrophils.177 Moreover, tocilizumab was found to upregulate serum miR-146a-5p levels in treated RA patients.